Asthma Clinical Trial
Official title:
Enhancing Pediatric Asthma Management
Inhaled corticosteroids taken on a daily basis have been proven to be the most effective treatment for children with persistent asthma. However, many pediatricians still do not prescribe daily corticosteroids to their asthmatic patients; this can lead to poor health outcomes among asthmatic children. This study will evaluate an interactive medical education program that focuses on improving pediatricians' asthma management skills and on encouraging increased corticosteroid use among their patients with asthma.
Asthma is a common childhood disease that affects over 9 million children in the United
States. In 1997, the National Heart, Lung, and Blood Institute (NHLBI) published a set of
guidelines aimed at improving the quality of patient care for individuals with asthma.
According to the guidelines, a daily dose of inhaled corticosteroids is considered the most
effective treatment for the long-term control of asthma. Despite this recommendation, many
pediatricians are not prescribing daily corticosteroids to asthmatic children who may
benefit from this treatment.
Continuing medical education (CME) is viewed as the primary method of keeping health care
providers informed of new research knowledge and the latest medical trends. While
traditional CME programs have not been successful in changing physician behavior, an
interactive program that offers skills development for implementing changes in the care and
treatment of asthmatic patients may prove effective. The purpose of this study is to
develop, implement, and evaluate an interactive asthma education program targeted towards
pediatricians. Specifically, the study will determine the program's effectiveness at
developing asthma management skills in pediatricians, including corticosteroid prescribing
practices, and improving asthma-related outcomes among their pediatric patients.
In this 5-year study, pediatricians will be randomly assigned to either an asthma education
intervention group or a control group. The intervention group will attend the enhanced
asthma education seminar, and the control group will attend a traditional lecture about
asthma. In Years 1 and 2, the intervention group will participate in a 2-hour focus group to
discuss barriers to adopting the NHLBI asthma guidelines for daily corticosteroid therapy. A
brief survey on this same topic will also be completed. During Year 2, physicians in the
intervention group will attend at least 5 hours of educational seminars designed to improve
adherence to the recommended guidelines. In Years 2 through 5, all physicians will complete
yearly questionnaires to assess barriers to corticosteroid prescription methods. Parents of
asthmatic patients treated by the pediatricians will take part in a 20-minute telephone
survey each year, and study researchers will review the medical records of each child.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|